The financial statements of Vertex Pharmaceuticals Incorporated for the three and six months ended June 30, 2022 and 2021 show an increase in income from operations. These statements detail the company's revenues, costs, expenses, and income, as well as comprehensive income, balance sheet, shareholders' equity, and cash flows. They also indicate growth in various financial metrics like net income and operating activities. Furthermore, there is a focus on additional financial aspects such as net income per common share, fair value measurements of financial assets and liabilities, marketable securities, contingent consideration, and intangible assets. The text also covers the company's investment strategy, use of foreign currency forward contracts, financial instruments carried at fair value, available-for-sale debt securities, accumulated other comprehensive income (loss), and changes in unrealized gains and losses on corporate equity securities.
The text discusses a pharmaceutical company's business operations, financial performance, liquidity, and capital resources as outlined in their Management's Discussion and Analysis of Financial Condition and Results of Operations. The company focuses on innovative medicines for various diseases, especially cystic fibrosis, and continues to develop treatments for other serious conditions. Financially, there was an increase in net product revenues and cash reserves, with the company anticipating sufficient funds for the next twelve months. They also detail their sources of liquidity, operating, investing, and financing activities, and future capital requirements. Additionally, the text addresses critical accounting policies, estimates, and recent accounting pronouncements relevant to the company's financial reporting and disclosures.
The text states that the information needed for quantitative and qualitative disclosures about market risk is referenced from Part II, Item 7A of the company's Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 9, 2022.
The management, including the chief executive officer and chief financial officer, evaluated the effectiveness of the company's disclosure controls and procedures as of June 30, 2022. They concluded that these controls were effective in ensuring that required information is recorded, processed, summarized, and reported within specified time periods. There were no changes in the internal control over financial reporting during the three months ended June 30, 2022 that materially affected the company.
The text provided states that there are currently no significant legal proceedings occurring.
The text discusses the presence of risk factors outlined in a Form 10-K filing and emphasizes forward-looking statements made in a Form 10-Q report. It mentions various expectations, including financial performance, clinical trials, regulatory approvals, product commercialization, and collaborations, as well as factors that could impact future events or results. It highlights that forward-looking statements are subject to uncertainties and risks and advises against placing undue reliance on them. The information serves as a cautionary note and stresses the importance of understanding potential impacts on the business.
In June 2021, the company's Board of Directors approved a $1.5 billion share repurchase program, valid until December 31, 2022. As of June 30, 2022, no shares were repurchased, leaving $499.7 million available for repurchases under the program. The company can buy shares through open market or privately negotiated transactions, following regulations, and under the 2021 Share Repurchase Program.
I see. Please go ahead and provide me with the text that you would like me to summarize.
I am ready to summarize the text whenever you are ready.
I understand that you will be sending me a text in parts and will summarize it after receiving all parts. Please go ahead and send me the text, and I will summarize it once I have received all parts.
The text is a list of exhibits associated with a company's financial report, including a credit agreement, certifications of the CEO and CFO under the Sarbanes-Oxley Act, and XBRL instance-related documents. It is concluded by signatures from the company's representative.
